Arch Biopartners Inc.
ARCH.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 32.39% | -67.77% | |||
| Gross Profit | -32.39% | 67.77% | |||
| SG&A Expenses | -17.42% | -74.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.25% | -71.98% | |||
| Operating Income | -2.25% | 71.98% | |||
| Income Before Tax | 10.73% | 66.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 10.73% | 66.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 10.73% | 66.50% | |||
| EBIT | -2.25% | 71.98% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 12.50% | 66.86% | |||
| Normalized Basic EPS | 11.43% | 66.98% | |||
| EPS Diluted | 12.50% | 66.86% | |||
| Normalized Diluted EPS | 11.43% | 66.98% | |||
| Average Basic Shares Outstanding | 1.48% | 1.26% | |||
| Average Diluted Shares Outstanding | 1.48% | 1.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||